EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC

Xu Wang, Cuiwei Liu, Zihan Xia, Ting Hu, Yuting Li, Dan Han, Yunjie Song, Yuxi Ma, Yanxia Zhao iD

Cancer Science · 2026

DOI: 10.1111/cas.70407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Xu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Losartan, Tumor Microenvironment, Radiation Tolerance, Triple Negative Breast Neoplasms. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Cancer Research Fund, Natural Science Foundation of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with limited therapeutic options. Radiotherapy (RT) is a cornerstone of TNBC treatment; however, preclinical studies suggest that RT may both stimulate and suppress immune responses within the tumor microenvironment (TME). While RT can enhance immune responses, it may also induce an immunosuppressive TME, contributing to radioresistance. The renin‐angiotensin system (RAS) is also involved in the immunosuppressive TME and tumor radioresistance. Previous research showed blocker of angiotensin II receptor (AGTR1), losartan, as a RAS inhibitor, could alleviate hypoxia, thereby enhancing RT efficacy. Our study shows that high levels of AGTR1 may confer a poor prognosis and radioresistance in TNBC, and innovatively demonstrates losartan could enhance the radiosensitivity of TNBC in an immune dependent way. Furthermore, we found losartan could inhibit tumor‐associated macrophages (TAMs) polarizing towards M2 phenotype, impedes the immunosuppressive function of myeloid‐derived suppressive cells (MDSCs) induced by RT, and ultimately up‐regulates the number and function of tumor‐infiltrating CD8 + T lymphocytes. Besides, RNA‐seq data reveals losartan impedes JAK2/STAT1 signaling activation upon irradiation, suppresses the interferon‐related DNA damage resistant signature (IRDS) expression and diminishes the immune suppressive factors PD‐L1 and IDO induced by irradiation in TNBC cells. Collectively, in our study, we investigate the role of losartan in radiosensitization and demonstrate losartan could reverse the immunosuppressive TME induced by RT in TNBC, which suggests that losartan combined with RT may represent a promising strategy for the treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LosartanTumor MicroenvironmentRadiation ToleranceTriple Negative Breast NeoplasmsHumansFemaleAnimalsCell Line, TumorReceptor, Angiotensin, Type 1MiceSignal TransductionTumor-Associated MacrophagesCD8-Positive T-LymphocytesMyeloid-Derived Suppressor CellsJanus Kinase 2Renin-Angiotensin SystemAngiotensin II Type 1 Receptor Blockers

Stichwörter der Autor:innen

TNBCimmunosuppressivelosartanradiotherapytumor immune microenvironment

Substanzen

LosartanReceptor, Angiotensin, Type 1Janus Kinase 2Angiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Precision Radiation Oncology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
  • Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China.
  • Laboratory of Experimental Cancer Research, Ghent University, Ghent, Belgium.

ORCID-Profile: Yanxia Zhao

Förderung

  • National Natural Science Foundation of China
  • Cancer Research Fund
  • Natural Science Foundation of Henan Province
  • Natural Science Foundation of Tibet of China
  • Hubei Hengrui Pharmaceutical Innovation and Development Joint Fund

Zitieren

APA

Wang, X., Liu, C., Xia, Z., Hu, T., Li, Y., Han, D., Song, Y., Ma, Y., & Zhao, Y. (2026). Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC. Cancer Science. https://doi.org/10.1111/cas.70407

Vancouver

Wang X, Liu C, Xia Z, Hu T, Li Y, Han D, et al. Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC. Cancer Science. 2026. doi:10.1111/cas.70407

BibTeX
@article{Wang2026,
  author = {Wang, Xu and Liu, Cuiwei and Xia, Zihan and Hu, Ting and Li, Yuting and Han, Dan and Song, Yunjie and Ma, Yuxi and Zhao, Yanxia},
  title = {Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70407}
}
Kostenlos starten →